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A B S T R A C T
The therapy with nanocompounds is widely used to treat Fe deficiency and an emerging trend to inhibit tu-
mor growth. The present work aims to address the management of different FeONP, comparing sucrose covered
FeONP and Fe nanoparticles in the form of the ferritin with non-particulated inorganic Fe (II) by enterocytes-like
colon cancer cell lines (Caco-2 and HT-29). Iron uptake results revealed significantly higher Fe incorporation in
the case of nanoparticulated Fe, first in the form of FeONP and second in the form of ferritin with respect to
inorganic Fe (II). Furthermore, the intracellular Fe fractionation, conducted by size exclusion chromatography
coupled on line to inductively coupled plasma mass spectrometry (SEC-ICP-MS) showed a significant increase of
the Fe-ferritin peak upon exposure of cells to the following compounds ferritin>FeONP>FeSO⁠4. Such results
point out that the sucrose coated FeONP released Fe into the cell cytosol that was used to replenish the exist-
ing cytosolic ferritin without inducing changes in the protein concentration. On the other hand, the increase of
the Fe-ferritin peak in cells exposed to ferritin as iron source is due to a significant increase on the intracellular
protein concentration, as proved by using an ICP-MS linked ferritin sandwich immune assay. Cell viability ex-
periments conducted with concentrations up to 1000µmolL⁠−1 (as Fe) of each compound under scrutiny did not
reveal significant differences among Fe species regarding global cellular toxicity. However, significant cell DNA
damage was detected when treating the cells with FeONP (500µmolL⁠−1).
1. Introduction
Iron deficiency anemia (IDA) results from an unbalanced iron ab-
sorption, transport and storage in the human body. For management
of IDA, oral iron supplementation is normally recommended, if inflam-
matory or blood loss processes are not occurring [1,2]. Simple ferrous
iron Fe(II) salts are most commonly used for this aim since they are
inexpensive and the iron is well absorbed. However, recently, these
compounds have been found responsible to induce undesirable changes
to bacteria of the colon and to increase pro-inflammatory signaling of
the gut epithelium enhancing systemic infection rates [3]. As alterna-
tive, some forms of ferric iron Fe(III) (e.g. ferric pyrophosphate) have
been proposed to be potentially better tolerated in the gut lumen than
Fe(II). Unfortunately, they are poorly absorbed by the intestine [4].
To improve the low tolerability and poor bioavailability of ionic Fe
species, different approaches have been taken [5]. In particular, Fe from
nanocompounds have shown to be more efficiently absorbed than the
ionic metal species in animal models without any detectable accumula-
tion in the gastrointestinal tract or other tissues [6].
In fact, the use of iron oxide/hydroxide nanoparticles (FeONP) cov-
ered with carbohydrate shells present an interesting alternative for iron
supplementation. They are currently indicated in cases of intolerance
or inadequate response to oral Fe and administrated as intravenous for-
mulations [7],8]. Nevertheless, some doubts still remain regarding the
bioavailability of some of these formulations since their expected dif-
fusion into the enterocytes seems to be not very effective. A way to
overcome the limited enterocyte uptake of the Fe-containing nanocom-
pounds is the modification of the NPs surface with specific ligands in
order to achieve receptor mediated NPs endocytosis. For this aim, fer-
ritin could be an ideal candidate [9]. Ferritin is an iron-binding pro-
tein with very high capacity to store Fe; up to 4500 atoms of Fe can
be accumulated in each molecule. It is composed by a protein cage in
which Fe is stored in the form of ferrihydrite (poly oxohydroxide Fe(III)
nanoparticles). Ferritin is an effective and bioavailable form of dietary
iron that has led to considerable interest for its potential use in “bio-
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fortification” of food crops [10]. Recent experiments in enterocyte-like
cells like Caco-2 strongly suggest that ferritin is taken up by ente-
rocytes via receptor-mediated endocytosis. The authors also suggest
that macropinocytosis, a secondary mechanism, might be activated at
high ferritin concentrations [11]. The capture of ferritin was originally
demonstrated in intestine [12], but also in white matter, lymphoid cells,
erythroid precursors, in the capsule of the adult kidney etc. In all of
these cell types, ferritin used an endocytic pathway and delivered iron
to the cytoplasm [13].
The second approach to enhance the uptake of nanocompounds by
enterocytes could be the use of Fe-NPs which contain a charged shell.
Studies on the effect of charge density and of the kind of charge (posi-
tive, negative) in non-phagocytic cells showed that charged iron oxide
particles are taken up better than their uncharged counterparts [14]. Al-
though the ‘average’ charges on the cell surface are negative, the cell
membrane also presents specific binding sites with cationic receptors
that allow interaction with anionic NPs, in a process described as an
“adsorptive endocytosis” pathway [15]. In this regard, Fe(III)-sucrose
complex (Venofer®) contains an Fe(III) core surrounded by sucrose that
provides a negative charge on the NPs outer shell. This complex is com-
monly used in intravenous iron formulations and has provided lower
anaphylactic reactions in patients that soon after administration recover
the adequate iron values in circulating blood [16]. Thus, the aim of
this work is the comparative evaluation of these two types of FeONPs
(sucrose coated and ferritin encapsulated) regarding enterocytes uptake
and management. Thus, the Fe cellular uptake, cytosolic Fe distribution
and management as well as Fe-induced cell toxicity will be addressed in




Two different ICP-MS instruments were used for this study: an Ag-
ilent Instrument 7700 (Agilent Technologies, Tokyo, Japan) and an
iCAPTQ ICP-MS (Thermo Fisher Scientific, Bremen, Germany) both with
H⁠2 as collision gas to eliminate polyatomic interferences. The iCAPTQ
ICP-MS was also used for Ru determination (ferritin analysis) using the
single quadrupole (SQ) mode. For the flow injection set-up, the solvent
was pumped using a peristaltic pump (0.5mLmin⁠−1) and the sample in-
jection was conducted using dual mode injection valve from heodyne,
model 9725 (Upchurch Scientific, Oak Harbor, Washington, USA).
For iron speciation in the cellular lysate, size exclusion chromatog-
raphy (SEC) was used. The mobile phase was pumped using a dual-pis-
ton liquid chromatographic pump (Shimadzu LC-20AD, Shimadzu Cor-
poration, Kyoto, Japan) equipped with a sample injection valve from
Rheodyne, fitted with a 20µL injection loop and a size exclusion chro-
matography column Superdex 200 10/300 GL (300mm×10mm i.d., GE
Healthcare Bio-Sciences, Sweden) having a fractionation range from 10
to 600kDa. The mobile phase flow rate was 0.7mLmin⁠−1. On line cou-
pling of the HPLC to the Vis/UV detectors was conducted by two differ-
ent Agilent instruments (Agilent Technologies, Tokyo, Japan) 1100 and
1260 Series monitored at 280nm and 380nm using a Diode Array De-
tector (DAD) detector (Agilent Technologies, Tokyo, Japan).
HR-TEM measurements were done in a JEOL-JEM 2100F (Tokyo,
Japan) transmission electron microscope with TEM operation voltage at
200kV to image iron NPs suspensions deposited on Cu grids. The instru-
ment permits also to obtain the elemental composition of the sample.
2.2. Chemicals and materials
All working solutions were prepared using 18MΩcm⁠−1 de-ionized
water obtained from a Milli-Q system (Millipore, Bedford, MA, USA).
The iron ICP-MS standard was purchased from Merck (Darmstadt, Ger-
many) and Ru ICP standard was obtained from Alfa Aesar (Alfa Aesar,
Karlsruhe, Germany). Ferritin standard from equine spleen were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). For the ferritin ICP-MS
linked immunoassay, biotinylated anti-ferritin mouse monoclonal anti-
body (3mgL⁠−1), labeled [Ru(bpy) ⁠3]⁠2+ anti-ferritin mouse monoclonal
antibody (6mgL⁠−1) and streptavidin covered magnetic microparticles
(0.72mgmL⁠−1) (Roche Diagnostics GmbH, Mannheim, Germany) were
used. Standard Venofer® solution was kindly provided by the Hema-
tology Group of the Hospital Central Universitario de Asturias (Oviedo,
Spain) in the form of an aqueous complex of polynuclear iron (III)-hy-
droxide in sucrose containing 20mg elemental Fe per mL. Upon recep-
tion, the content of the vial (5mL) was separated into aliquots of 1mL
and stored at −4°C until further use. Successive dilutions of the par-
enteral solution were conducted in 0.9% NaCl, as stated by the man-
ufacturer. FeSO⁠4·7 H⁠2O used were purchased from Sigma-Aldrich. SEC
separation was done using a mobile phase containing 50mmolL⁠−1 am-
monium acetate (Merck), pH=7.4 at 0.7mLmin⁠−1.
2.3. Cell culture and lysis
The human colorectal adenocarcinoma cell lines (HT29 and Caco-2
cells) were obtained from the Biotechnological and Biomedical Assays
in the Technical Services of the University of Oviedo. Cells were grown
in T-25 flasks with IMEM medium (LabClinic) and supplemented with
9% FBS (Gibco, Life Technologies, Madrid, Spain) at 37°C in a 5%
CO⁠2 atmosphere. Then, the cells were washed with 10mmolL⁠−1 PBS
(pH=7.4, three times to remove any iron traces from the growing me-
dia) and then trypsinized. Cells were placed in six well plates. The num-
ber of cells in the case of HT-29 ranged 0.8–1.0×10⁠6 and 0.5–0.6×10⁠6
in the case of the Caco-2 counted using a Neubauer chamber. After 24h,
the different Fe-containing compounds were added. The compounds
were added using a syringe filter with 0.2µm Supor® sterile membrane
in order to avoid bacterial contamination. Cells were harvested after
48h. The quantitative results have been referenced to the wet weight of
cells [17]. This was done by washing the cells three times with PBS, re-
moving the supernatant by centrifugation and finally weighting the cell
pellet using a precision balance.
Washed cells were lysed using three cycles of freezing/thawing
using liquid nitrogen. Then, the cellular lysate was centrifuged
(12,000g×20min) and the supernatant was collected for further analy-
sis.
2.4. Total cellular iron and Fe speciation
An aliquot of the cell lysate previously acidified with 0.1% HNO⁠3
was taken for total Fe determination by ICP-MS obtained by continuous
nebulization after optimizing the sample consumption. The results were
obtained for six independent cell cultures. The Fe uptake, within each
cell line, was determined using paired Student t tests to compare treat-
ments with negative controls, and linear regression analyses to study
whether the response increased with concentration.
A second aliquot of the lysate was used for ferritin determina-
tion which will be described in the following section. Additionally, an
aliquot of that was also injected into the SEC-ICP-MS and SEC-Vis/UV
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2.5. Sandwich immunoassay with Ru detection for ferritin determination
Aliquots of 50µL of independent cell lysates (corresponding to six
different cell cultures) were mixed with the biotinylated ferritin-specific
antibody and the Ru-labeled ferritin-specific antibody to form a sand-
wich complex as described elsewhere [18]. The signal of Ru was trans-
formed into ferritin concentration and the values plotted as the mean
with error bars corresponding to the standard deviation to compare
treatments with control.
2.6. Comet assay
This assay is used in order to detect the presence of DNA strand
breaks in HT-29 cells. After the incubations, we diluted the cells to ob-
tain 650 cells per sample holder and carried out the assay as described
by Sar et al. [19]. Cells were visualized at 400 times magnification with
an Olympus DP-70 CCD-coupled camera (from the Scientific and Tech-
nical Services of the University). The photos were analyzed with the
Komet 5 program (Kinetic, UK). The statistical analysis of mean values
was carried out with the Mann-Whitney U test.
2.7. Cytotoxicity assay
A Cell Counting Kit-8 (CCK-8) assay kit Sigma-Aldrich was used to
evaluate the toxicity of the different treatments in the cells. The cells
were dispersed into a 96-well plate and after 24h the compounds were
added as described before. CCK-8 solution was then added to each well
and the plate was incubated for 2h. The absorbance was measured at
450nm using a microplate reader. Every treatment at every concentra-
tion was done in triplicate and the cytotoxicity results are given as the
mean with the error bars corresponding to the standard deviation.
3. Results
3.1. Core size in water and in cell growing media
TEM images of the FeONPs used for this work are collected in Fig.
1 corresponding to the NPs solubilized in water (A) and also in the cell
growing media (B) (depleted in Fe). The sphere-like structures can be
seen in both cases corresponding to the iron hydroxides cores. The mea-
surement of the core diameter resulted in 4.0±0.6nm for the sucrose
coated FeONPs and 7.5±1.2nm for the ferritin encapsulated FeONPs
solubilized in water. The solubilization of the sucrose coated FeONPs in
the cell growing media produced an interaction between the particles
(probably ascribed to dipolar interactions) that resulted in NPs aggrega-
tion. As illustrated in Fig. 1B (left column), small clusters of about 5–8
nanoparticles (8-20nm) and large agglomerates up to 200nm (see point-
ing arrows in the Fig. 1B) were observed by TEM (also by DLS, data not
shown). Such effect was not observed in the ferritin encapsulated NPs.
3.2. Iron uptake by Caco-2 and HT-29 cell lines
Cells were incubated with the different Fe nanocompounds and
FeSO⁠4 at 100 and 500µmolL⁠−1 Fe at 37°C during 48h. It is impor-
tant to address that special cell culture conditions were taken by us-
ing an Fe-depleted growing media and the minimum percentage of fetal
Fig. 1. TEM images of the sucrose coated FeONPs solubilized in water (A) and in the cell growing media (B). The solubilization in the cell growing media produced an interaction between
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bovine serum (9%) to preserve cell viability and decrease Fe contri-
bution other than the treatments. After cell lysis (the cell number in
the case of HT-29 was 1.1×10⁠6 cells and 0.8×10⁠6 in the Caco-2, re-
spectively) the Fe content in the lysate was measured by flow injec-
tion-ICP-MS and the results are plotted in Fig. 2 (A and B for HT-29 and
Caco-2 cell lines, respectively). As can be observed, FeONPs coated with
sucrose provided highest uptake in both cellular models and at both
assayed concentrations followed by the ferritin encapsulated Fe. Both
treatments were more efficiently incorporated than the ionic form of Fe
and the uptake increased almost linearly with increasing exposure con-
centrations, in particular in the HT-29 cell model. However, higher up-
take was observed in all cases in the Caco-2 model.
3.3. Cytosolic speciation
In addition to the total iron concentration, Fe cytosolic distribution
studies were conducted by coupling size exclusion chromatography to
UV–VIS and ICP-MS detection. Fig. 3 shows the Fe chromatographic
profiles obtained for the cytosol of HT-29 cell line (similar results were
obtained in the case of Caco-2). The inset corresponds to the TEM fig-
ure of the sucrose FeONPs treated HT-29 cells. The two main Fe-con
taining species eluted in the chromatograms at 11 and 15min, respec-
tively. Depending on the source of Fe used, a different distribution was
observed among these two species. The peak eluting at 15min corre-
sponds to the retention time of the ferritin standard and this species
showed increasing intensity upon exposure to sulfate<venofer<fer-
ritin (Fe column recovery on each injection was >90%). However, since
the Fe stoichiometry in ferritin is variable (can vary from 200 to 4500
Fe atoms per molecule of ferritin) and ICP-MS provides just elemental
information, it was not possible to directly address whether the ferritin
concentration was increased upon exposure or the Fe-load into the fer-
ritin did it. Therefore, complementary immunochemical experiments to
determine, specifically, the ferritin concentration had to be conducted
and are shown in the following section.
Regarding the species eluting at about 11min, it corresponds to
species of large molecular weight (>600kDa). In the case of the cells
treated with ferritin, this species is ascribed to the formation of
oligomers of ferritin, as reported by other authors that can occur when
the protein is isolated [20]. In the case of the cells exposed to the NPs,
this peak corresponds to the presence of nanoparticles (either isolated
or aggregated) as confirmed by the injection of Venofer directly in this
column (see Supplementary material).
Fig. 2. Fe incorporation in both cellular models, HT-29 (A) and Caco-2 cells (B), for each Fe compound (n=3 independent cell cultures respectively). FeONPs coated with sucrose pro-
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Fig. 3. Fe chromatographic profiles obtained by SEC-ICP-MS for the cytosol of HT-29 cell
line. The retention time of the ferritin standard corresponds to 15min. The inset shows the
TEM picture of the cell cytosol incubated with FeONPs.
3.4. Ferritin quantitative analysis
Ferritin concentration was obtained by using a previously developed
ICP-MS linked immunoassay based on a sandwich experiment with a
Ru-labelled antibody [16]. The obtained results are shown in Fig. 4 for
the HT-29 cell line, where the concentration (ngmL⁠−1) of the protein in
the lysate is shown for every treatment. There are not a significant dif-
ferences between control and sulfate treated cells regarding ferritin con-
centration and slightly lower values are obtained for the cells exposed to
sucrose coated FeONPs. However, the only significant increment is ob-
served when the cells are directly exposed to ferritin as nanocompound
pointing out that this species is incorporated into the cell cytosol di-
rectly through the specific ferritin receptors.
3.5. Cellular cytoxicity and DNA damage
Since Fe is a potent redox compound through Fenton reaction, it is
important to take into account that high Fe uptake might be associated
to an increase in reactive oxygen species (ROS) formation and there-
fore, higher cellular toxicity. In fact, recent reports reveal that nanopar-
ticle-induced modulation of iron and ROS levels within cancer cells and
the tumor microenvironment could provide a new strategy for cancer
treatment [21]. For this aim, cell viability was evaluated at different
concentrations of the three species using the cell counting kit (CCK-8)
Fig. 4. Ferritin concentration obtained in the HT-29 cells treated with the three Fe-con-
taining compounds (500µM as Fe) and measured using an ICP-MS based sandwich im-
munoassay [16].
which has proved to be more sensitive than other assay like MTT, etc.
The results are plotted in Fig. 5 for HT-29 and Caco-2, respectively.
In both cases, highest descent in cell viability is observed in cells
exposed to FeONPs coated with sucrose which diminished cell viability
to 75% at 1000µmolL⁠−1 Fe. Thus, a potent redox effect at these con-
centrations and with this time of exposure can be ruled out. However,
first tests in order to address initial genotoxicity originated by free rad-
icals produced during Fe metabolism were conducted by the Comet as-
say and using cells treated with H⁠2O⁠2 as positive control. Although both
cell models proved to be suitable for this assay, Caco-2 turned out to be
more sensitive to manipulation and prone to DNA unspecific degrada-
tion. Therefore, the results presented here refer to the HT-29 cell line.
Fig. 6A shows the electropherograms corresponding to the control cells,
cells exposed to FeONPs coated with sucrose as well as the positive con-
trol of cells treated with H⁠2O⁠2. In this case, it was possible to observe a
partial DNA degradation in the treatment with FeONPs that provided a
tail percentage of about 25% (Fig. 6B), which was significantly different
from the other treatments and from the control cells. Thus, initial DNA
damage seems to be occurring during cells exposure to this compound
that is not detectable in the case of the ferritin or Fe(II) exposed cells.
4. Discussion
The two main mechanism of internalization of Fe-NPs in cells are
compared in this work: through specific receptors (ferritin) and by “un-
specific” endocytosis (sucrose coated FeONPs). In addition, both mech-
anisms are compared with the uptake of Fe(II) salts (most conventional
formulation for iron supplementation) in two enterocyte-like cell mod-
els. Since NPs uptake and biological function depends not only on the
surface charge but also on the shape and size, it is important to con-
sider the effect of the cell growing medium on the studied NPs. The
first observation was the partial aggregation of the sucrose FeONPs once
solubilized in the cell growing media (which was not observed in the
ferritin NPs). This is probably ascribed to the presence of the compo-
nents of the incubation medium (e.g. proteins) that induce electrosta-
tic interaction of the NPs. Such interaction has been also reported to
help decreasing cytotoxicity for many NPs but results in a significant
Fig. 5. Cell viability results using the CCK-8 kit for HT-29 (A) and Caco-2 cells (B), at dif-
ferent concentrations of the three species. Highest descent in cell viability is observed in
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Fig. 6. Electropherograms corresponding to the control cells, cells exposed to FeONPs coated with sucrose as well as the positive control of cells treated with H⁠2O⁠2(A). It is observed a
partial DNA degradation in the treatment with FeONPs that provides a tail percentage of about 25% (B), the highest in comparison with the others treatments.
change in their mean size (moving from individual NPs with a core size
of 4±1nm to aggregates up to 200nm) [22]. However, since entero-
cytes have shown to preferentially ingest particles in the range between
100 and 200nm, aggregation does not represent an issue regarding up-
take, in this case, and might be even advantageous with respect to the
use of smaller NPs [23].
Iron uptake experiments in the two cell models by ICP-MS revealed
highest Fe incorporation in the case of the sucrose coated FeONPs. Val-
ues of about 0.14pg Fe per cell in the cells exposed to 100µmolL⁠−1
Fe and 0.35pg Fe per cell in the cells exposed to 500µmolL⁠−1 in the
HT-29 were obtained. These values are, as average, 1.7-fold higher than
those obtained when using ferritin as nanoparticulated formulation and
about 3-fold higher than in the case of Fe (II). In addition, the Caco-2
model shows higher uptake for all the compounds when compared to
HT-29 but the relative differences among treatments are consistent in
both cell models, in particular at the higher doses. Out of these results
it can be extracted that unspecific NPs endocytosis is prevalent to the
uptake through specific receptors (either using DMT1 as for Fe(II) or fer-
ritin specific receptors). Comparing ferritin and Fe(II), it has been doc-
umented that ferritin uptake at higher concentrations can be also dri-
ven by endocytosis and this can serve as the explanation for the simi-
lar uptake values observed for Fe(II) and ferritin at low concentrations
(100µmolL⁠−1) and the differences found at higher doses (500µmolL⁠−1)
in both cell models. In addition, the endocytosis of the FeONPs seems to
occur directly from the nanoparticulated form and TEM figures permits
to detect, clearly, the presence of these NPs (both, dispersed and aggre-
gated) in the cytosol of both cell models.
The fractionation of the incorporated Fe in the cytosol of the treated
cells was conducted using SEC-ICP-MS. The results of Fig. 3
(SEC-ICP-MS) revealed that ferritin is the main Fe containing protein
within the cell cytosol and the absolute protein concentration is re-
ported in Fig. 4. Since ferritin can allocate a variable concentration of
Fe within the protein cage (up to 4500 atoms of Fe per molecule of fer
ritin), the cellular uptake of Fe(II) as sulfate produced a significant in-
crease of the stored Fe within the existing cytosolic ferritin and an in-
crease in the Fe profile. In addition, the ferritin treated cells uptake and
accumulate this protein by increasing the measured intracellular ferritin
concentration in respect to the control and, subsequently, the Fe sig-
nal in the SEC-ICP-MS. Finally, the results of the treatment with NPs,
which showed slightly lower protein concentration but higher Fe signal
by SEC-ICP-MS, reveal that the Fe loading of ferritin is increased upon
exposure to these FeONPs.
Such increase could be ascribed to the release of Fe(III) due to the
partial degradation of the NPs that could be further reduced to Fe(II)
and be incorporated into the existing cytosolic ferritin. In addition, an-
other fraction of the FeONPs can be directly endocyted and stored by
the enterocytes providing an intense Fe peak at the void volume of the
chromatography (see Fig. 4). This conclusion was extracted from the
fact that a similar chromatographic profile was obtained when the su-
crose coated FeONPs were directly injected into the system (see Supple-
mentary information). However, the two experiments (SEC-ICP-MS and
ferritin analysis) are necessary and complementary to obtain these con-
clusions.
Negligible cellular toxicity, even taking into account the high Fe up-
take (up to 2% in the case of the sucrose coated FeONPs) was been de-
tected in all the evaluated treatments and cell models. Just concentra-
tions above 500µmolL⁠−1 provided a viability decrease above 20% (see
Fig. 5). However, the number of oxidative DNA modifications induced
by reactive species arising from iron-driven reactions is high, according
to the literature [24]. The degree of genotoxic damage in an individual
cell can be easily measured with the comet assay which is, in principle,
simple and inexpensive to perform but is also very sensitive. With this
assay we it is possible to show, not only the indirect formation of ROS,
but the effect of ROS on the DNA damage (one of the most biomarkers
usually chosen to measure the effects of ROS in cells) that can be de-
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tion of the DNA induced toxicity (more sensitive) through the Comet
assay revealed a significant DNA damage in the doses of 500µmolL⁠−1
for the sucrose coated FeONPs, which is probably related to the higher
uptake of this nanocompound in the HT-29 cell model. Such result is
not surprising since iron is a potent redox element that might undergo
(bio)chemical oxidation/reduction within cells. In this case, a reduction
has occurred (since the uptake of Fe by ferritin occurs only with Fe(II)
and the sucrose coated FeONPs contain Fe(III)) and thus, the generation
of free radicals within the cell cytosol is almost ensured.
5. Conclusions
This study has confirmed that although higher Fe uptake has been
observed when using negatively charged sucrose coated FeONPs, the
most efficiently Fe storage (in a biologically compatible form) is in the
form of ferritin NPs. The sucrose coated FeONPs provide a high level
of intracellular nanoparticulated Fe that could be further converted into
ionic Fe species. Since Fe is a potent redox element, the consequences
of such release would need to be stablished and initial DNA damage has
been observed. On the other hand, the administration of Fe-ferritin in-
corporates Fe in cells in a more efficient manner than Fe(II) salts and
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